Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch(mut)) Meeting Abstract
| Authors: | Ferrarotto, R.; Metcalf, R.; Rodriguez, C. P.; Muzaffar, J.; Even, C.; Perez, A.; Van Herpen, C. M. L.; Oliva, M.; Xia, B.; Bowles, D. W.; Popovtzer, A.; Winquist, E.; Wirth, L. J.; Hao, D.; Kang, H.; Hotte, S. J.; Stemmer, S. M.; Mehra, R.; Worden, F. P.; Ho, A. L. |
| Abstract Title: | Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch(mut)) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301747 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.6046 |
| Notes: | Meeting Abstract: 6046 -- This meeting was also held virtually -- Source: Wos |
